#
Title
1

Neurological Involvements of Multiple Myeloma: A Comprehensive Clinical Review

2

2026 European Guidelines for Management of Aneurysmal Subarachnoid Haemorrhage

3

Neurological Assessment and Management of Autonomic Failure

4

Intracranial Arterial Dolichoectasia: A Comprehensive Review

5

N-Acetylcysteine in Ischemic Stroke: A Systematic Review

6

Thiamin and Folic Acid for Cognitive Impairment in Hemodialysis Patients

7

Advances in the Treatment of Autoimmune Nodopathy

8

Advances in Guillain-Barré Syndrome: Diagnosis, Biomarkers, and Management

9

GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

10

Anti-Amphiphysin Antibody Positive Autoimmune Syndrome

11

Shingles Vaccination and Reduced Dementia Risk

12

Approach to Asymptomatic HyperCKemia - EAN Guidelines

13

Predictive T-Cell Biomarkers for Checkpoint Inhibitor Response in PML

14

Practical Strategies for SCIg Maintenance Therapy in CIDP Patients

15

Treatment of Spinal Cavernous Malformations: A Systematic Review

16

Augmenting Diagnostic Yield From Genomic Testing in Neurological Diseases

17

Spinal and Bulbar Muscular Atrophy: Pathogenesis and Therapeutic Horizons

18

Phase 3 Trial of Brepocitinib in Dermatomyositis

19

Are Patients with Essential Tremor at Increased Risk of Parkinson's Disease?

20

Efficacy of Hyperbaric Oxygen in Neurological Disorders

21

Recent Advances in Targeted Therapies for Adult Gliomas

22

Modafinil for Excessive Daytime Sleepiness in Narcolepsy: A Meta-Analysis

23

The European Medicines Agency's Assessment of Lecanemab and Donanemab for Alzheimer’s Disease

24

The Vital Role of PET/CT in NF1 Cancer Surveillance

25

A Diagnostic Assay for Multiple Sclerosis Based on EBV

26

Radiologically Isolated Syndrome: A Practical Clinical Guide

27

Stenting vs. Shunting for Sight-Threatening Intracranial Hypertension

28

AI-Driven Biomarkers in Neurology: A Narrative Review

29

Pompe Disease - Advances in Diagnosis and Management

30

Hallmarks of Secondary Headaches

31

Del-desiran Therapy for Myotonic Dystrophy Type 1

32

Long-Term Efficacy and Safety of Tofersen in SOD1-ALS Patients

33

Movement Disorders and Oculomotor Abnormalities in Whipple's Disease

34

Acute Disseminated Encephalomyelitis (ADEM): Review

35

A refresher on abnormal spontaneous EMG activities

36

A Review of Posterior Reversible Encephalopathy Syndrome (PRES)

37

General neurologists guide for diagnosis of atypical parkinsonian disorders

38

Refractory, intensive care–dependent NMDAR encephalitis

39

LRP4 Antibodies in Suspected Myasthenia Gravis Diagnosis

40

Autoimmune encephalitis during the COVID-19 pandemic

41

Dermatomyositis: Modern Diagnostic Paradigms

42

The HTLV-1 Neurological Complex: Beyond Myelopathy

43

Alpha-Lipoic Acid Efficacy in Managing Diabetic Polyneuropathy Symptoms

44

Etiological Screening Strategies for Small Fiber Neuropathy

45

Tenecteplase in acute central retinal artery occlusion, a phase 3 Clinical Trial

46

How to use blood-based biomarkers to diagnose Alzheimer’s disease

47

Brief Review - 2026 Guidelines for Early Management of Acute Ischemic Stroke

48

Multifocal Motor Neuropathy: Clinical Features, Diagnosis, and Treatment Bibliography

49

Stiff Person Syndrome: Clinical Spectrum, Diagnosis, and Management

50

Management of Dementia with Lewy Bodies, A Review

51

Seronegative Autoimmune Encephalitis

52

Guidelines for the Diagnosis and Clinical Management of Cavernous Malformations of the Brain and Spinal Cord

53

Distinguishing Vestibular Vertigo from Posterior Stroke

54

2025 In Review - MS and Autoimmune CNS Disorders

55

2025 In Review - Epilepsy

56

2025 In Review - Stroke and Neurovascular Disorders

57

2025 In Review - Movement Disorders

58

2025 In Review - Neuromuscular Disorders

59

GLP-1 Receptor Agonists: Efficacy, Safety, and Neurological Frontiers

60

Treating psychiatric comorbidities in patients with epilepsy.

61

The prognosis and treatment outcomes for individuals with focal epilepsy

62

Global surge of early-onset Parkinson’s disease (EOPD) 

63

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

64

Long-term outcomes of seizures and epilepsy in patients with untreated cerebral cavernous malformations

65

Phenotype-Genotype Correlations in Myelin Protein Zero (MPZ) Variants

66

Cardiac Involvement in Myotonic Dystrophy Type 1 and 2

67

Rituximab Therapy for Resistant Myasthenia Gravis

68

Advances in Treatment of Myasthenia Gravis

69

Peripheral Neuropathy: A Comprehensive Review

70

Diagnostic Controversies in Chronic Inflammatory Demyelinating Polyneuropathy

71

Early Use of Rituximab in New-Onset Generalized Myasthenia Gravis: RINOMAX Trial

72

CAR-T cell therapy, neurological risks and potential use

73

Active Inference Model of Functional Neurological Disorder

74

Are COVID-19, RSV, and Influenza vaccines safe and effective?

75

Outcome Measures for Adult Becker Muscular Dystrophy Progression

76

2025 ILAE 2025 updated seizure classification

77

Myasthenia Gravis 2025 Updated Management Guidelines from the Association of British Neurologists

78

Iatrogenic Cerebral Amyloid Angiopathy (CAA) and CAA related inflammation (CAA-ri)

79

Early Tirofiban After Thrombolysis for Ischemic Stroke (ASSET-IT trial)

80

Friedreich’s ataxia - A Comprehensive Look

81

CADASIL Unmasked

82

TTR Familial Amyloidosis Genotype-Phenotype Correlation

83

Spinal Bulbar Muscular Atrophy: Canadian Best Practice Recommendations

84

2025 Revised Criteria for Vascular Cognitive Impairment

85

Idiopathic Normal Pressure Hydrocephalus: Incidence, Progression, Diagnosis and Treatment

86

Glycine Receptor Antibody Associated Progressive Encephalomyelitis Clinical Outcomes (PREM)

87

Neurological complications of drug misuse

88

Minimally invasive surgery for intracerebral hemorrhage

89

A blood test to distinguish Parkinson's disease and Dementia with Lewy bodies

90

Navigating Postanoxic Status Epilepticus

91

Migraine Prevention Review: Therapies, Efficacy, and Safety

92

Using serum NFL and antibody titer to monitor disease activity in CASPR2/LGI1 autoimmune encephalitis

93

Peripheral blood monocytes can predict impending relapses and disability worsening in MS

94

Late Effects of Traumatic Brain Injury

95

Oseltamivir Reduces Pediatric Neuropsychiatric Events During Influenza

96

Health Anxiety in Neurological Settings

97

Laser interstitial thermal therapy for mesial temporal lobe epilepsy

98

Myasthenia Gravis Autoantibody Heterogeneity and Therapeutic Implications

99

VCP Multisystem Proteinopathy

100

Updated AAN Guidelines on prolonged disorders of consciousness

101

Psychiatric comorbidities are an independent risk factor for unfavorable outcomes in Autoimmune Encephalitis

102

Timing of Anticoagulation for Stroke and Atrial Fibrillation

103

Treating Small Vessel CNS Vasculitis: Early Intervention and Remission

104

Neurofilament Light Chain Assays in MS Management

105

Nucleoside reverse transcriptase inhibitor use and reduced risk of Alzheimer’s disease

106

Lipoprotein a and Stroke Recurrence: A Systematic Review

107

Serum NFL as a biomarker for CIDP Diagnosis and Treatment

108

Upadacitinib for Giant-Cell Arteritis, SELECT-GCA Trial Results

109

Assessing Functional Motor Weakness: A Practical Guide

110

Treating Neuropsychiatric Symptoms in Parkinson's Disease

111

Rituximab Use in Anti-NMDAR Antibody-Mediated Encephalitis Relapse Prevention

112

Understanding Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders

113

Repeat Expansion Disorders in Neurology

114

Neurological IgG4-Related Disease: Diagnosis and Management

115

Long-Term Ravulizumab Efficacy and Safety in Generalized Myasthenia Gravis

116

The Second European Carotid Surgery Trial (ECST-2)

117

Inebilizumab Trial in Myasthenia Gravis

118

Brain MRI as prognostic factor in Anti NMDA Encephalitis

119

Efgartigimod Efficacy and Safety in CIDP - ADHERE and ADHERE+ Trials

120

Telitacicept Shows Strong Efficacy for Generalized Myasthenia Gravis

121

C5 vs FcRn inhibitors for generalized myasthenia gravis

122

MMF for anti-NMDA antibody maintenance

123

European Guidelines for Assessment and Management of Neurogenic Bladder

124

ADVANCE CIDP -IVIG Clinical Trial

125

Multifocal Motor Neuropathy - A Comprehensive Review

126

Bone marrow transplantation for MS, ECTRIMS Recommendation

127

Do glucose lowering drugs prevent dementia?

128

Serum NfL as a Diagnostic and Prognostic ALS Biomarker

129

Stress and cryptogenic stroke in young adults

130

Using AI Vision in Neurology

131

European Guidelines on PET imaging for brain metastasis

132

Pyridostigmine for Orthostatic Hypotension

133

MoCA vs MMSE for Frontotemporal Dementia

134

Prognosis of Postanoxic Status Epilepticus

135

Idiopathic intracranial hypertension - diagnosis

136

rTMS Trial for Cognitive Impairment in ALS

137

Rozanolixizumab in Generalized Myasthenia Gravis - OLE

138

CSF-Serum Free Kappa Light Chain Index - Optic Neuritis Diagnosis

139

ABN Guidelines on Multiple Sclerosis Disease-Modifying Treatment

140

Neurological complications of immune checkpoint inhibitors

141

TMPN Trial in ALS

142

A Practical Approach to the Diagnosis of Neuropathies

143

Therapeutics in Inflammatory Muscle Diseases

144

Treatment of Cluster Headaches

145

Clinical Trial of Zilucoplan in ALS

146

Is Multiple Sclerosis a Virus-Induced Gliopathy?

147

DDPX Antibody Associated Encephalitis - A Review

148

Antidepressant use and cognitive decline in patients with dementia: a national cohort study

149

Cost of New Neurologic Medications

150

rTMS and Aphasia Therapy Post-Stroke, a Clinical Trial

151

Periodic EEG Patterns

152

Acceptance and Commitment Therapy

153

Endovascular therapy versus best medical care for acute ischemic stroke with distal medium vessel occlusion

154

Exenatide in Parkinson’s disease phase 3 trial

155

No long‑term benefits from resistance training on brain grey matter volumes in active older adults at retirement age

156

Tirofiban Efficacy in Stroke

157

International Consensus Guidance for Managing Glucocorticoid-Related Neuromuscular Complications

158

Consensus Statement on Continuous EEG in Critically Ill Patients

159

AI-Optimized Anti-Seizure Treatment and EEG in Brain Injury

160

MOG Antibody Testing in Clinical Practice

161

LUMINESCE A phase 3 trial clinical trial of satralizumab for generalized myasthenia gravis

162

Lipid Variability and Cognitive Decline in Older Adults

163

Blood Biomarkers and MS Diagnosis

164

Long-Term Ocrelizumab Treatment for Early-Stage Relapsing MS

165

The Spectrum of Genetic Risk in Alzheimer's Disease

166

Central Nervous System Manifestations in Sjögren's Disease

167

Intravenous Thrombolysis for Minor Stroke - A Systematic Review and Meta-analysis

168

Cancer risk in multiple sclerosis patients and DMT

169

Neurogenic Orthostatic Hypotension in Parkinson's Disease

170

Cognitive decline after heart failure

171

Friedreich Ataxia: A 30-Year Retrospective

172

Breaking Bad News in ALS/MND: The A-L S-PIKES Protocol

173

Plasma Neurofilaments as ALS Biomarkers

174

APOE's Role in Cerebral Amyloid Angiopathy

175

Intra-arterial Tenecteplase After Posterior Circulation Recanalization - ATTENTION-IA trial

176

WHO Classification of Central Nervous System Tumors, Fifth Edition - A flashback to 2021

177

Tele-EEG for Critically Ill Patients: A Multicenter RCT

178

Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study

179

Autoimmune Nodopathies and IgG4 Antibodies in Neurology

180

Anti-IgLON5 Disease: A Decade of Discovery and Unanswered Questions

181

SAHARA Trial: Transfusion Strategies in Aneurysmal Subarachnoid Hemorrhage

182

CRISPR-Cas9 Gene Editing for ATTR Cardiomyopathy

183

Introduction to Weekly Deep Dive Neurology Podcast

184

Memantine in Amyotrophic Lateral Sclerosis

185

Rituximab for Idiopathic Inflammatory Myositis: A Systematic Review and Meta-analysis

186

Vutrisiran for ATTR cardiomyopathy

187

Long-Term Safety of fSCIG for CIDP Maintenance Therapy

188

Neurofilament Light Chain and GFAP in Mood and Anxiety Disorders

189

Efficacy and Safety of IVIG Maintenance Therapy in Generalized Myasthenia Gravis

190

Anticoagulation strategy for patients presenting with ischemic strokes while using a direct oral anticoagulant:

191

Early Atogepant Efficacy in Migraine Prevention

192

2024 AASM Clinical Practice Guideline: Restless Legs Syndrome and PLMD Treatment